The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Precigen's PRGN-2012 and UltraCAR-Ts offer groundbreaking therapies. Read why PGEN stock is a strong pick, with major ...

PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...

NEW YORK – The US Food and Drug Administration has accepted Precigen's biologics license application for PRGN-2012 (zopapogene imadenovec), a gene therapy that it is developing for recurrent ...

A regulatory decision on odronextamab for R/R FL is expected by July 30, 2025. The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA ...

Precigen has won U.S. Food and Drug Administration priority review for its application seeking approval of its proposed PRGN-2012 gene therapy for adults with recurrent respiratory papillomatosis ...

(RTTNews) - Precigen, Inc. (PGEN), a biopharmaceutical company specializing in gene and cell therapies, on Tuesday said that the U.S. Food and Drug Administration or FDA has granted priority ...

Precigen on Tuesday said a green light would make PRGN-2012 the only FDA-approved therapeutic for the treatment of adults with the disorder, which is a lifelong neoplastic disease of the upper and ...

for the treatment of adults with recurrent respiratory papillomatosis (RRP). RRP is a rare neoplastic disease caused by an infection with human papillomavirus (HPV) 6 or 11. It is characterized by ...

Underneath we present a selection of stocks filtered out by our screen. Overview: Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering ...

Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa., Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ ...